Skip to main content
SpringerLink
Log in

In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody

  • Original Article
  • Monoclonal Antibody, CD19, Immunoconjugate, Chimeric Antibody, Lymphoma, Idarublcin, Immunochemotherapy, Anti-CD19
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Mouse monoclonal antibodies to CD19 detect an antigenic determinant expressed exclusively on the surface of B lymphocytes, and have previously been shown to be potentially useful therapeutic reagents for human B cell lymphoma. We report the production and characterization of a mouse/human chimeric antibody, cCD19, with potent in vivo antitumour activity. The genes encoding the variable domains for heavy (VH) and light (VL) chains were subcloned into eukaryotic expression vectors containing human constant region genes (IgG1 and κ), and co-transfected into non-secreting Sp2/0 mouse myeloma cells. Intraperitoneal administration of cCD19 produced inhibition of growth of subcutaneous CD19+ Sultan human B lymphoma tumours inscid/scid mice. When the antibody was administered 18 and 20 days after subcutaneous tumour inoculation, an approximately 30% reduction in tumour size was noted by day 29. cCD19 faithfully mimicked the in vitro binding characteristics of mCD19 as (a) the chimeric antibody was shown by flow cytometry to bind exclusively to cell lines that expressed CD19, (b) cCD19 was able to inhibit the binding of mCD19 on CD19+ cells completely and (c) the affinity of binding of the two antibodies was not significantly different [K a=(2.03±1.5)×108]. In biodistribution studies, up to 14.8% of the total injected antibody dose per gram of tissue was localized in CD19+ Sultan tumours at 24 h approximately, 14.4% was present in the tumors at 48 h and about 13.7% at 72 h. These levels were comparable to mCD19 administered in the same fashion. cCD19 conjugated to idarubicin was specifically and strongly cytotoxic to CD19+ cells cultured in vitro, and demonstrated an IC50 of 0.17 μM, similar to that of mCD19 (0.32 μM) and approximately 14-fold greater than the IC50 of free idarubicin. The specific cytotoxic capacity of cCD19 and its likely reduced immunogenicity suggest that it may potentially be of use in the treatment of refractory B cell lymphoma in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ (1992) Initial experience in treating human lymphoma with a combination of bispecific abtibody and saporin. Int J Cancer Suppl 7:73

    Google Scholar 

  2. Bradford MM (1976) A rapid and sensitive method of quantitation of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem 72:248

    PubMed  Google Scholar 

  3. Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS (1990) Antitumour activity of Adriamycin(hydrazone-linked) immunoconjugates compared with free Adriamycin and specificity of tumor cell killing. Cancer Res 50:6608

    PubMed  Google Scholar 

  4. Dillman RO (1990) Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconjugates Radiopharm 3:1

    Google Scholar 

  5. Ey PL, Prowse SJ, Jenkin CR (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A Sepharose. Immunochemistry 15:429

    PubMed  Google Scholar 

  6. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli MF, Stirpe F (1992) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195

    PubMed  Google Scholar 

  7. Forni L (1979) Reagents of immunofluorescence and their use for studying lymphoid cell populations. In: Lefkovitis and B Pernis (eds) Immunological methods. I. Academic Press, New York, pp 151

    Google Scholar 

  8. Gobuty A, De Nardo GL, De Nardo SJ (1992) Lym-1 radioimmunotherapy: a case history of how we do it. Antibody Immunoconjugates Radiopharm 5:13

    Google Scholar 

  9. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE (1990) Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol 8:1083

    PubMed  Google Scholar 

  10. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Bolliger KP, Gorick BD, Hughes-Jones NC, Hoogenboom HR, Winter G (1993) Human anti-self antibodies with high specificity from phage display libraries. EMBO J 12:725

    PubMed  Google Scholar 

  11. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA, Nadler LM (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79:576

    PubMed  Google Scholar 

  12. Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H (1988) Remission induction in non-hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH 1H. Lancet: 21394

  13. Harris NS (1974) Plasma cell surface antigens on human blood lymphocytes. Nature 250:507

    PubMed  Google Scholar 

  14. Haruta Y, Seon BK (1986) Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83:7898

    PubMed  Google Scholar 

  15. Haspel MV, McCabe RP, Pomato N, Janesch NJ, Knowlton JV, Peters LC, Hoover HC Jr, Hanna MG Jr (1985) Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45:3951

    PubMed  Google Scholar 

  16. Hastings A, Morrison SL, Kanda S, Saxton RE, Irie RF (1992) Production of a murine/human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Res 52:1681

    PubMed  Google Scholar 

  17. Hekman A, Honselaar A, Vuist WMJ, Sein JJ, Rodenhuis S, Bokkel Huinink WW ten, Somers R, Rumke PH, Melief CJM (1991) Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32:364

    PubMed  Google Scholar 

  18. Hendgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA, Niethammer D (1992) A phase-I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199

    PubMed  Google Scholar 

  19. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE, Epenetos AA (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403

    PubMed  Google Scholar 

  20. Hunter WM, Greenwood FC (1962) Preparation of iodine-131-labelled human growth hormone of high specific activity. Nature 194:495

    PubMed  Google Scholar 

  21. Issacs JD, Clark MR, Greenwood J, Waldmann H (1992) Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 148:3062

    PubMed  Google Scholar 

  22. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1(anti-CD20) antibody. N Engl J Med 329:459

    PubMed  Google Scholar 

  23. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220

    PubMed  Google Scholar 

  24. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H (1993) Long-term remission of intractable systemi vasculitis with monoclonal antibody therapy. Lancet 341:1620

    PubMed  Google Scholar 

  25. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielmans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349

    PubMed  Google Scholar 

  26. Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, Shochat D, Weeler RW, LoBuglio AF (1992) Phase I trial of iodine-131-chimeric B72.3(human IgG4) in metastatic colorectal cancer. J Nucl Med 33:23

    PubMed  Google Scholar 

  27. Mount PF, Sutton VR, Li W, Burgess J, McKenzie IFC, Pietersz GA, Trapani JA (1995) A chimeric(mouse/human) anticolon antibody, c30.6, inhibits the growth of human colorectal cancer xenografts inscid/scid mice. Cancer Res 54:6160

    Google Scholar 

  28. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated and malignant B lymphocytes. J Immunol 131:244

    PubMed  Google Scholar 

  29. Novak-Hofer I, Amstutz HP, Haldemann A, Blaser K, Mogenthaler J-J, Blauenstein P, Schubiger PA (1992) Radiolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J Nucl Med 33:231

    PubMed  Google Scholar 

  30. Orlandi R, Gussow DH, Jones PT, Winter G (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 86:3833

    PubMed  Google Scholar 

  31. Peterson BM, Bass BL, Bates HR, Chandysson PL, Harmon JW (1993) Use of the radiolabeled murine monoclonal antibody, In-111-CYT-103, in the management of colon cancer. Am J Surg 165:137

    PubMed  Google Scholar 

  32. Pietersz GA, Smyth MJ, McKenzie LFC (1988) Immunochemotherapy of a murine thymoma with idarubicinmonoclonal antibody conjugates. Cancer Res 48:926

    PubMed  Google Scholar 

  33. Press OW, Eary JF, Badger CC, Martin PJ, Applebaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Donnall Thomas E, Bernstein ID (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1(anti-CD37) antibody. J Clin Oncol 7:1027

    PubMed  Google Scholar 

  34. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B cell malignancies. Cancer Res 49:4906

    PubMed  Google Scholar 

  35. Riechmann L, Clark MR, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323

    PubMed  Google Scholar 

  36. Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, Seccamani E, Lazzari S, Fagioli L, Franceschi G, Sarti G, Riva N, Natali PG, Zardi L, Scassellati GA (1992) Treatment of intracraneal human glioblastoma by direct intratumoral administration of I-131-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51:7

    PubMed  Google Scholar 

  37. Rowland AJ, McKenzie IFC, Pietersz GA (1993) Preclinical investigation of the antitumour effects of anti-CD-19-idarubicin immunoconjugates. Cancer Immunol Immunother 37:195

    PubMed  Google Scholar 

  38. Sata K, Tsuchiya T, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53:851

    PubMed  Google Scholar 

  39. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann New York Acad Sci 51:660

    Google Scholar 

  40. Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910

    PubMed  Google Scholar 

  41. Smyth MJ, Pietersz GA, Classon BJ, McKenzie JFC (1986) The specific targeting of chlorambucil to tumours. J Natl Cancer Inst 76:503

    PubMed  Google Scholar 

  42. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, Hellstrom KE (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212

    PubMed  Google Scholar 

  43. Van Dongen GAMS, Leverstein H, Roos JC, Quak JJ, Brekel MWM, Van der Lingen A, Martens HJM, Castelijns JA, Visser GWM, Meijer CJLM, Teule GJJ, Snow GB (1992) Radioimmunoscintigraphy of head and neck cancer using99mTc-labeled monoclonal antibody E48 F(ab′)2. Cancer Res 52:2569

    PubMed  Google Scholar 

  44. Verhoeyen ME, Saunders JA, Price MR, Marugg JD, Briggs S, Broderck EL, Eida SJ, Mooren ATA, Badley RA (1993) Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78:364

    PubMed  Google Scholar 

  45. Vervoordedonk SF, Merle PA, Leeuwen EF van, Schoot CE van der, Borner AE von dem, Slapper-Cortenbach IC (1994) Ec gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood 83:1632

    PubMed  Google Scholar 

  46. Vervoordeldonk SF, Merle PA, Leeuwen EF van, Borne AE von dem, Slapper-Cortenbach IC (1994) Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 73 [Suppl 3]:1006

    PubMed  Google Scholar 

  47. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052

    PubMed  Google Scholar 

  48. Weiner LM, Harvey E, Padavic-shaller K, Willson JKV, Walsh C, LacCreta F, Khazaeli MB, Kirkwood JM, Haller DG (1993) Phase-II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 13:110–116

    PubMed  Google Scholar 

  49. Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y (1991) Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 69:411

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austin Research Institute, Austin Hospital, Studley Road, 3084, Heidelberg, Victoria, Australia

    Geoffrey A. Pietersz, Li Wenjun, Vivien R. Sutton, Jane Burgess, Ian F. C. McKenzie & Joseph A. Trapani

  2. Flinders Medical Centre, 5042, Bedford Park, South Australia, Australia

    Heddy Zola

Authors
  1. Geoffrey A. Pietersz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Wenjun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivien R. Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jane Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ian F. C. McKenzie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heddy Zola
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joseph A. Trapani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pietersz, G.A., Wenjun, L., Sutton, V.R. et al. In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody. Cancer Immunol Immunother 41, 53–60 (1995). https://doi.org/10.1007/BF01788960

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01788960

Key words

Search

Navigation